Focal Adhesion Kinase (FAK) tyrosine 397E mutation restores the vascular leakage defect in endothelium‐specific FAK‐kinase dead mice

Focal adhesion kinase (FAK) inhibitors have been developed as potential anticancer agents and are undergoing clinical trials. In vitro activation of the FAK kinase domain triggers autophosphorylation of Y397, Src activation, and subsequent phosphorylation of other FAK tyrosine residues. However, how...

Descripción completa

Detalles Bibliográficos
Autores principales: Alexopoulou, Annika N, Lees, Delphine M, Bodrug, Natalia, Lechertier, Tanguy, Fernandez, Isabelle, D'Amico, Gabriela, Dukinfield, Matthew, Batista, Silvia, Tavora, Bernardo, Serrels, Bryan, Hodivala‐Dilke, Kairbaan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2017
Materias:
Original Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518444/
https://www.ncbi.nlm.nih.gov/pubmed/28444899
http://dx.doi.org/10.1002/path.4911

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518444/
https://www.ncbi.nlm.nih.gov/pubmed/28444899
http://dx.doi.org/10.1002/path.4911

Ejemplares similares